Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05849883
Other study ID # 551/STD/PML/2020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 10, 2020
Est. completion date February 3, 2021

Study information

Verified date May 2023
Source PT Kalbe Farma Tbk
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study was conducted to investigate whether 20 mg omeprazole capsules manufactured by PT. Dankos Farma for PT. Hexpharm Jaya is bioequivalent to its reference product, 20 mg Losec® capsules manufactured by AstraZeneca AB, Sweden, imported by PT. AstraZeneca Indonesia.


Description:

Thirty six healthy subjects were given a single dose of 20 mg omeprazole capsules or 20 mg Losec® capsules with 240 mL of water. Then the blood samples for omeprazole were drawn and analyzed using LCMS/MS. All subjects sample plasma were analyzed for pharmacokinetic evaluation.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date February 3, 2021
Est. primary completion date January 14, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 44 Years
Eligibility The inclusion criteria were healthy male or female subjects who/with: - had read the subject information and signed informed consent documents - age range from 18 - 55 years - body mass index between 18-25 kg/m2 - had a normal electrocardiogram - had the blood pressure within normal range (systolic 90-120 mmHg and diastolic 60-80 mmHg) - had the heart rate within normal range (60 - 100 bpm) - had absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening. - accepted to use protection (condom) before any intercourse with their spouse throughout the study Excluded from the study were: - those who were pregnant and/or nursing women (for women). - those with history of contraindication or hypersensitivity to omeprazole, or other proton pump inhibitor drugs or other ingredients in the drugs or a history of serious allergic reaction to any drug, a significant allergic disease, or allergic reaction. - those with a history or presence of medical condition which might significantly influence the pharmacokinetic of the study drug, e.g. chronic gastrointestinal disease, diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or cardiovascular disease. - those with a history or presence of any coagulation disorder or clinically significant hematology abnormalities. - those who were using any medication (prescription or non-prescription drug, food supplement, herbal medicine), particularly the medication known to affect the pharmacokinetic of the study drug, within one week prior to the drug administration day. - those who had participated in any clinical study within 3 months prior to the study (<90 days). - those who had donated or lost 300 ml (or more) of blood within 3 months prior to the study. - those who smoked more than 10 cigarettes a day - those who were reactive to SARS CoV-2 test. - those with a history of travelling to another city within the last 14 days - those with a history of direct contact with a COVID-19 positive person in the subject's neighborhood - those with a history or present of sore throat, fever (with temperature more than 37°C) or dyspnea with in the last 14 days - those who were positive to HIV, HBsAg, and HCV tests (to be kept confidential). - those with a history of drug or alcohol abuse within 12 months prior to screening for this study. - those who were unlikely to comply with the protocol, e.g uncooperative attitude, inability to return for follow up visits, poor venous access.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Omeprazole 20 mg Capsules
Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production

Locations

Country Name City State
Indonesia PT Pharma Metric Labs Jakarta Pusat DKI Jakarta

Sponsors (2)

Lead Sponsor Collaborator
PT Kalbe Farma Tbk PT Pharma Metric Labs

Country where clinical trial is conducted

Indonesia, 

References & Publications (4)

Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl. 1989;166:33-40; discussion 41-2. doi: 10.3109/00365528909091241. — View Citation

Dubcenco E, Beers-Block PM, Kim LP, Schotland P, Levine JG, McCloskey CA, Bashaw ED. A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety. Clin Transl Sci. 2017 Sep;10(5):387-394. doi: 10.1111/cts.12475. Epub 2017 Jun 15. — View Citation

Kim YK, Yoon S, Yu KS, Kim BH, Yim SV. A bioequivalence study of two omeprazole formulations in healthy male volunteers. Int J Clin Pharmacol Ther. 2016 Nov;54(11):928-934. doi: 10.5414/CP202580. — View Citation

Oosterhuis B, Jonkman JH. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion. 1989;44 Suppl 1:9-17. doi: 10.1159/000200098. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Geometric Mean Ratio of Cmax The ratio between maximum concentration of test drug and reference drug after drug administration before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
Primary Geometric Mean Ratio of AUCt The ratio between area under curve from 0 to 10 hours of test drug and reference drug before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
Secondary Pharmacokinetics Parameter of Cmax Maximum plasma concentration (Cmax) before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
Secondary Pharmacokinetics Parameter of AUCt Area Under Curve from 0 to 10 hours (AUCt) before dosing and at 15, 30, 45, 60, 75, 90, 105 minutes, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 5, 6, 8, and 10 hours after drug administration
See also
  Status Clinical Trial Phase
Completed NCT05468879 - Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects N/A
Not yet recruiting NCT06395129 - Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
Completed NCT02293057 - Gender-Responsive Drug Use Treatment for Juvenile Justice Girls N/A
Completed NCT01941108 - Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care N/A
Completed NCT01380613 - Neighborhoods, Networks, Depression, and HIV Risk Phase 2
Withdrawn NCT00914719 - Alcohol Use and Sexual Risk: An Intervention N/A
Recruiting NCT03671629 - Pharmacist Intervention to Reduce Drug-related Readmissions Among the Elderly N/A
Completed NCT03290391 - Linking Infectious and Narcology Care-Part II Phase 4
Completed NCT04008927 - A Community-based Intervention Among Active Drug Users in Montpellier N/A
Completed NCT03627546 - HCV Seek, Test and Rapid Treatment for Young PWID N/A
Not yet recruiting NCT03967262 - Secondary Prevention and Recidivism Reduction in Trauma Patients N/A
Completed NCT03079856 - Drug Use and Sexual Risk Behaviors Among Emerging Adults in the ER N/A
Completed NCT03855410 - Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention N/A
Terminated NCT02457949 - The Impact of Alternative Social Assistance Disbursement on Drug-related Harm N/A
Completed NCT06238154 - Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds Phase 4
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Recruiting NCT04717856 - Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA N/A
Completed NCT00249496 - Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1 N/A
Recruiting NCT05597865 - Assessing the Feasibility of Economic Approaches to Prevent Substance Abuse Among Adolescents N/A
Completed NCT05553054 - Drug Wastage : Observational Study in Intensive Care Units in France

External Links